
Neil Baum, MD, and Randy Bauman discuss their tips to making the transition from practice seller to buyer as seamless as possible to keep patient retention rates high.

Neil Baum, MD, and Randy Bauman discuss their tips to making the transition from practice seller to buyer as seamless as possible to keep patient retention rates high.

Persistent clinical benefit was seen among a small group of patients with metastatic renal cell carcinoma who had to discontinue therapy with the PD-1 inhibitor nivolumab (Opdivo) because of immune-related adverse events, according to a study presented at the Genitourinary Cancers Symposium in Orlando, FL.

Administration of broad-spectrum antibiotics in patients with metastatic renal cell carcinoma (RCC) undergoing treatment with immune checkpoint inhibitors may have a negative effect on the efficacy of the immunotherapy drugs, according to the results of a recent retrospective analysis.

An investigatory bladder cancer agent was associated with a 12-month high-grade recurrence-free survival of 35% for patients with Ta/T1 disease, researchers reported.

Cancer patients taking certain immunotherapy drugs may be more susceptible to developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a recent study.

When trying to determine how much is enough when saving for retirement, there are many elements that must be considered. Plus, weigh these pros and cons when deciding how long to receive payments from an immediate annuity.

Urologic oncology fellow, Ariel Schulman, MD, shares some tips to help residents make research a positive experience.

A recent study has found that genetic predictors of normal PSA levels in healthy men could be used to improve the accuracy of PSA-based prostate cancer screening.

In these videos, high-volume stone surgeons demonstrate novel approaches to classification, visualization, and treatment of stones.

Nivolumab (Opdivo) is the second in class of immune checkpoint inhibitors approved for advanced bladder cancer-treatments that are having “tremendous responses across a spectrum of cancers,” says Leonard G. Gomella, MD.

Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.

Using multi-parametric magnetic resonance imaging to triage men with high serum PSA could save about one-fourth of patients from having transrectal ultrasound-guided prostate biopsy, according to a recent study.

The addition of hormonal therapy in post-RP is “practice changing,” study author says.

Other products discussed include an updated prostate tissue ablation device, a contrast agent for voiding ultrasonography, a bladder cancer test and more.

Urologists who view electronic medical record documentation as a burden are turning to scribes. Scribes, many say, relieve them of that burden, freeing urologists and other providers to focus on patient care.

Ashley Li, BS, chief scribe in the University of California, San Francisco’s urologic oncology and melanoma departments, says urology scribes help streamline patient care.

State policy makers are working to ensure that NPs and physicians will collaborate within the health care team as they look to modernize NP licensure framework.

Henry Rosevear, MD, examines how the political notion of a “post-truth” world has seeped into medicine.

This article will discuss the concept of practice valuation and how to go from abstraction to dollars or how to make dollars and “cents” of the process of putting a dollar value on a urologic practice.

"Rather than making a blanket statement regarding continued follow-up, we need to consider the pathologic features commonly known to increase the risk of [prostate cancer] recurrence-concurrent medical problems, the patient’s age at recurrence, PSA doubling time, longevity in the family, etc," writes J. Brantley Thrasher, MD.

The risk for biochemical recurrence of prostate cancer remains relatively high even 10 years after radical prostatectomy, but it does not appear to be influenced by a positive family history of prostate cancer or a family or personal history of other cancer, according to a study analyzing data from the prospective German Familial Prostate Cancer database.

Salvage lymph node dissection results in an immediate complete PSA response in about one-third of patients with rising PSA and nodal recurrence following local therapy for prostate cancer, according to German researchers.

High-grade proctitis after radical radiation therapy with neoadjuvant or adjuvant hormonal therapy is significantly less likely in patients taking angiotensin-converting-enzyme inhibitors.

Each year, the Office of the Inspector General at the Department of Health and Human Services publishes a summary of its activities and a work plan for the coming year. What follows is a summary of new topics in the FY2017 work plan that may be of interest to urologists.


Adherence to guidelines for the use of combination radiation therapy and androgen deprivation therapy in the United States for the treatment of high-risk or locally advanced prostate cancer has decreased over time, according to data presented by Paolo Dell’Oglio, MD.

Despite the excruciating nature of kidney stones, many people can't manage to lower their risk by simply drinking more liquid. Now, a new study finds that one potential tool-a water bottle with a built-in consumption sensor and smartphone link-accurately tracks how much people drink.


The Affordable Care Act's controversial contraceptive coverage mandate requires most private health plans to provide cost-free coverage of female contraception. Reproductive health advocates in many states are pressing for new laws that include vasectomy in those covered services.

“Be honest and forthright but try to do it as compassionately as possible,” one urologist advises.